Enoxaparin - NDC Database (Page 9)

175 records found
Page:First PagePrevious Page9
72603-165 Mar 15, 2023
Enoxaparin Sodium 30 mg/.3ml Subcutaneous Injection, Solution by Northstar Rxllc
72603-175 Mar 15, 2023
Enoxaparin Sodium 40 mg/.4ml Subcutaneous Injection, Solution by Northstar Rxllc
72603-185 Mar 15, 2023
Enoxaparin Sodium 60 mg/.6ml Subcutaneous Injection, Solution by Northstar Rxllc
72603-195 Mar 15, 2023
Enoxaparin Sodium 80 mg/.8ml Subcutaneous Injection, Solution by Northstar Rxllc
72603-205 Mar 15, 2023
Enoxaparin Sodium 100 mg/ml Subcutaneous Injection, Solution by Northstar Rxllc
72603-215 Mar 15, 2023
Enoxaparin Sodium 120 mg/.8ml Subcutaneous Injection, Solution by Northstar Rxllc
72603-225 Mar 15, 2023
Enoxaparin Sodium 150 mg/ml Subcutaneous Injection, Solution by Northstar Rxllc
76420-086 Nov 17, 2014
Enoxaparin Sodium 40 mg/.4ml Intravenous; Subcutaneous Injection, Solution by Asclemed USA, Inc.
81952-123 Mar 15, 2023
Enoxaparin Sodium 30 mg/.3ml Subcutaneous Injection, Solution by Hepalink USA Inc.
81952-124 Mar 15, 2023
Enoxaparin Sodium 40 mg/.4ml Subcutaneous Injection, Solution by Hepalink USA Inc.
81952-126 Mar 15, 2023
Enoxaparin Sodium 60 mg/.6ml Subcutaneous Injection, Solution by Hepalink USA Inc.
81952-128 Mar 15, 2023
Enoxaparin Sodium 80 mg/.8ml Subcutaneous Injection, Solution by Hepalink USA Inc.
81952-130 Mar 15, 2023
Enoxaparin Sodium 100 mg/ml Subcutaneous Injection, Solution by Hepalink USA Inc.
81952-132 Mar 15, 2023
Enoxaparin Sodium 120 mg/.8ml Subcutaneous Injection, Solution by Hepalink USA Inc.
81952-135 Mar 15, 2023
Enoxaparin Sodium 150 mg/ml Subcutaneous Injection, Solution by Hepalink USA Inc.
Page:First PagePrevious Page9
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.